ISSN: 1859 - 2872
Results of treatment for recurrent metastatic colon cancer with bevacizumab-folfiri regimen
Main Article Content
Keywords
Metastatic colorectal cancer, bevacizumab, folfiri
Abstract
Objective: To assess tumor response, progressive-free survival and toxicity of bevacizumab-folfiri regimen for patients with recurent metastatic colon cancer. Subject and method: A retrospective and prospective study was done on 31 patients with recurrent metastasis colon cancer, who were received bevacizumab-folfiri treatment at 108 Military Central Hospital from January 2016 to July 2018. Result: The complete response rate was 12.9%, the overall response rate was 32.3%. Median progressive-free survival was 10.5 ± 0.9 months. The toxicities were at level 1, 2. Conclusion: Bevacizumab-folfiri regimen is an effective choice and well tolerated in patients with recurrent metastatic colon cancer.
Article Details
References
1. New Global Cancer Data: GLOBOCAN 2018 | UICC. , accessed: 13/08/2019.
2. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA A Cancer J Clin 69(1): 7-34.
3. Van Cutsem E, Nordlinger B, Cervantes A, Group ESMO Guidelines Working Group (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21(5): 93-97.
4. Shojaei F (2012) Anti - angiogennesis therapy in cancer: Current challenges and future perspectives. Cancer Left 320: 130-137.
5. Stathopoulos GP, Batziou C, Trafalis D et al (2010) Treatment of colorectal cancer with and without bevacizumab: A phase III study. Oncology 78: 376.
6. Herbert H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342.
7. Sobrero A, Ackland S, Clarke S et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2): 113-119.
8. Kochi M, Akiyama Y, Aoki T et al (2013) FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: A JACCRO CC-03 multicenter phase II study. Cancer Chemother Pharmacol 72(5): 1097-1102.
2. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA A Cancer J Clin 69(1): 7-34.
3. Van Cutsem E, Nordlinger B, Cervantes A, Group ESMO Guidelines Working Group (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21(5): 93-97.
4. Shojaei F (2012) Anti - angiogennesis therapy in cancer: Current challenges and future perspectives. Cancer Left 320: 130-137.
5. Stathopoulos GP, Batziou C, Trafalis D et al (2010) Treatment of colorectal cancer with and without bevacizumab: A phase III study. Oncology 78: 376.
6. Herbert H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342.
7. Sobrero A, Ackland S, Clarke S et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2): 113-119.
8. Kochi M, Akiyama Y, Aoki T et al (2013) FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: A JACCRO CC-03 multicenter phase II study. Cancer Chemother Pharmacol 72(5): 1097-1102.
Article Sidebar
How to Cite
Nguyen ThanhN., Pham VanH., Nguyen ThanhB., Tran Thi Ha T., & Le VanQ. (2019). Results of treatment for recurrent metastatic colon cancer with bevacizumab-folfiri regimen. Tạp Chí Y Dược lâm sàng 108, 14(5). Retrieved from https://tcydls108.benhvien108.vn/index.php/YDLS/article/view/79